Search





Search





Markets
/
Stocks
/
nasdaq-cdna
/

CareDx Inc

CDNA

Add to Watchlist

19.970USD

-0.520-2.54%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

1.03BMarket Cap

LossP/E TTM



CareDx Inc

19.970

-0.520-2.54%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of CareDx Inc

Currency: USD Updated: 2026-05-15

Key Insights

CareDx Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 33 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 25.80.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

CareDx Inc's Score

Industry at a Glance

Industry Ranking

33 / 382

Overall Ranking

129 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

CareDx Inc Highlights

StrengthsRisks

CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the provider of genomics-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its lab product portfolio includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA. It also offers a diverse portfolio of digital solutions to transplant centers.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 35.49% year-on-year.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD .

Undervalued

The company’s latest PE is -126.01, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 52.46M shares, decreasing 15.72% quarter-over-quarter.

Held by First Eagle Investment

Star Investor First Eagle Investment holds 575.37K shares of this stock.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

25.800

Target Price

+25.92%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-15

The current financial score of CareDx Inc is 7.60, ranking 73 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 117.70M, representing a year-over-year increase of 38.99%, while its net profit experienced a year-over-year increase of 127.13%.

Score

Industry at a Glance

Previous score

7.60

Change



Financials

8.63

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

2.76

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.06

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.54

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

CareDx Inc's Company Valuation

Currency: USD Updated: 2026-05-15

The current valuation score of CareDx Inc is 6.45, ranking 266 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -126.01, which is -119.98% below the recent high of 25.18 and -9.71% above the recent low of -138.25.

Score

Industry at a Glance

Previous score

6.45

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 33/382

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-15

The current earnings forecast score of CareDx Inc is 7.56, ranking 288 out of 382 in the Biotechnology & Medical Research industry. The average price target is 24.50, with a high of 28.00 and a low of 14.00.

Score

Industry at a Glance

Previous score

7.75

Change

-0.19

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

25.800

Target Price

+25.92%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

CareDx Inc

CDNA

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Ionis Pharmaceuticals Inc

IONS

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-15

The current price momentum score of CareDx Inc is 7.29, ranking 79 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 22.69 and the support level at 17.70, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.43

Change

-0.14

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.449

Neutral

RSI(14)

47.123

Neutral

STOCH(KDJ)(9,3,3)

15.481

Sell

ATR(14)

1.333

High Vlolatility

CCI(14)

-164.892

Sell

Williams %R

63.564

Sell

TRIX(12,20)

0.482

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

20.804

Sell

MA10

20.989

Sell

MA20

21.035

Sell

MA50

19.014

Buy

MA100

19.299

Buy

MA200

17.184

Buy

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of CareDx Inc is 10.00, ranking 1 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 101.54%, representing a quarter-over-quarter decrease of 11.87%. The largest institutional shareholder is Ron Baron, holding a total of 3.16M shares, representing 6.11% of shares outstanding, with 55.28% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

4.02M

-2.36%

Baron Capital Management, Inc.

Star Investors

3.16M

State Street Investment Management (US)

2.74M

+6.67%

ARK Investment Management LLC

Star Investors

2.14M

-1.58%

Deerfield Management Company, L.P.

2.19M

Boston Partners

901.93K

+2776.51%

Gagnon Securities LLC

1.77M

+2.63%

Braidwell LP

1.59M

-27.38%

Amova Asset Management Co., Ltd.

1.45M

-16.86%

Risk Assessment

Currency: USD Updated: 2026-05-15

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of CareDx Inc is 5.82, ranking 35 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 2.48. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.